Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Short Bowel Syndrome
Conditions
Short Bowel Syndrome
Trial Timeline
Jul 1, 2009 → Nov 1, 2013
NCT ID
NCT00767364About Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R) is a phase 1 stage product being developed by Merck for Short Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00767364. Target conditions include Short Bowel Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00767364 | Phase 1 | Completed |
Competing Products
20 competing products in Short Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin + leuprorelin | Eli Lilly | Phase 3 | 77 |
| Growth Hormone | Eli Lilly | Approved | 85 |
| Pancreatic Enzyme | AbbVie | Phase 2 | 52 |
| Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone | AstraZeneca | Phase 3 | 77 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| r-metHuLeptin | Amgen | Phase 1 | 32 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Somatotropin growth hormone recombinant human | Pfizer | Approved | 84 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Genotropin + Genotropin | Pfizer | Phase 3 | 76 |
| GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment | Pfizer | Approved | 84 |
| Genotropin | Pfizer | Phase 2/3 | 64 |
| glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| ZP1848 | Zealand Pharma | Phase 2 | 49 |
| glepaglutide + Placebo | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide 10 mg | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Nutropin [Somatropin (rDNA origin) for injection] | Ipsen | Approved | 82 |